Efficacy and Safety of select Flavonoids for the Treatment of Uncomplicated SARS-CoV-2 COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202010537777617

Enrollment

200

Registered

2020-10-15

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory

Interventions

Experimental pharmaceutical preparation micronized flavonoids intervention 2000mg daily

Placebo Control group

Experimental pharmaceutical preparation of micronized flavonoids. Dose dependence verif. 1500mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 18-80 y.o.presenting with positive PCR test for COVID-19.

Exclusion criteria

Exclusion criteria: Patients on chronic medications that require P450 enzyme to be uninhibited. (example - atorvastatin, blood thinners, heart arrhythmia medication)

Design outcomes

Primary

Measure	Time frame
Days from patient presentation to negative nasopharyngeal PCR result	—

Secondary

Measure	Time frame
Count of viral RNA copies via qPCR or digital PCR	—

Countries

Kenya

Contacts

Public ContactLeah Kigondu

Program Manager

leah@emske-phytochem.com+254708294132

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026